Relationship between Hypomagnesemia and Dyslipidemia in Type 2 Diabetes Mellitus


  • Sri Muthukumaran Medical College and Research Institute, Department of Biochemistry, Chennai, India
  • Sri Ramachandra Hospital, Central Laboratory, Chennai, India


Magnesium is an important macro mineral in the mammalian cells. It is a cofactor for many enzymes involved in lipid metabolism like lipoprotein lipase, pyrophosphatase etc . In magnesium deficiency, these enzymes are defective and leads to dyslipidemia in type 2 diabetic patients. Objective : To observe the association between hypomagnesemia and dyslipidemia in type 2 diabetic patients. Methodology: A case control South Indian population study consist ed of control group (40 healthy individuals) and case group (203 patients who were diagnosed as type 2 diabetes). Serum magnesium and lipid profile was analyzed in blood samples using standard kits in fully automated analyzer. The data was analyzed using Student's 't' test and correlation coefficient. Result: In the present study, a significant low serum magnesium levels (p<0.01) in case group was observed when compared to control group . A significant decreased cholesterol levels (p<0.05) and serum HDL levels (p<0.001) was observed in case group when compared to control group. In case group, we found a significant increased triglycerides (p<0.05) and LDL levels (p<0.001) when compared to control group. A positive correlation was observed between magnesium and cholesterol (r = 0.195, p<0.01), magnesium and LDL (r = 0.202, p<0.01), magnesium and total cholesterol HDL ratio (r = 0.142, p<0.05) in the case gr oup. Conclusion: We observed hypomagnesemia in type 2 diabetes patients with dyslipidemia.


Hypomagnesemia, Lipoprotein Lipase and Dyslipidemia.

Subject Discipline

Pharmacy and Pharmacology

Full Text:


Diwan AG, Pradhan AB, D. Lingojwar, Krishna KK, Singh P and Almelkar SI. Serum zinc, chromium and magnesium levels in type 2 diabetes. Int Dia Dev Cteries 2006; 26:3.

Sharma A, Dabla S, Agarwal PR, Barjatya H, Kochar DK and Kotheri RP. Serum magnesium: an early predictor of course and complications of diabetes mellitus. J India Assoc 2007; 105: 16.

Chhabra N, Chhabra S and Ramessur K. Hypomagnesemia and its implications in type 2 diabetes mellitus: a review article. Webmedcentral 2012; 3[12]: WMCOO3878.

Chetan. P. Hans, Sialy R and Devi. D. Bansal. Magnesium deficiency and diabetes mellitus. Current Science 2002; 83: 12.

Jennifer. L. King, Rita. J. Miller, James. P. Blue, William. D. O’Brien and John. W. Erdman. Inadequate Dietary magnesium in take increases atherosclerotic plaque development in rabbits. Nutr Res 2009; 29[5]: 343-349.

Gueux E, Rayssiguier Y, Piot MC and Alcindor L. Reduction of plasma lecithin cholesterol acyl transferase activity by acute magnesium deficiency in the rats. J Nutr 1984; 114: 1479-1483.

Kaur J, Prabhu KM and Thakur LC. Serum magnesium levels in ischaemic cerebrovascular disorders: a case control study in north Indian population. JPBMS 2012; 17[2]: 17.

Rasanoff A and Seeling MS. Comparison of mechanism and functional effects of magnesium and statin pharmaceutical. J Am Coll Nutr 2004; 23[5]: 5015-5055.

Carman GM and Han GS. Roles of phosphatidate phosphatase enzymes in lipid metabolism. Trends Biochem Sci 2006; 31[12]: 694-9.

Salem M, Kholoussi S, Kholoussi N and Fauzy R. Malondialdehyde and trace element levels in patients with type 2 diabetes mellitus Archives of Hellenic medicine 2011; 28[1]: 83-88.

Sales CH and Campos Pedrosa LF. Magnesium and diabetes mellitus. Clinical Nutrition 2006; 25: 554-562.

Guize L, Le Heuzey J. Y, Blanchand D, Benoit MO, Pelissier E, Paris M, et al. Magnesium deficiencies in Cardiovascular disease. Arch Mal Coeur Vaiss 1984; 77: 41-47.

Haglin L, Backman L and Tornkvist B. A. structural equation model for assessment of links between changes in serum triglycerides, urate, glucose and changes in calcium, phosphate and magnesium in type 2 diabetes and non diabetes metabolism. Cardiovascular Diabetology 2011; 10: 116.

Rasheed H, Elahi S and Ajay H. Serum magnesium and atherogenic lipid fractions in type 2 diabetic patients of Lahore, Pakistan. Biol Trace Elem Res 2012; 148[2]: 165-9.

Mishra S, Padmanaban P, Deepti GN, Sarkar G, Sumathi S and Toora BD. Serum magnesium and dyslipidemia in type 2 diabetes mellitus. Biomedical research 2012; 23[2]: 295-300.

Aruna V and Ambikadevi K. Hypomagnesemia a cofactor for atherogenesis in non insulin dependent diabetes mellitus. Int J Pharm Bio Sci 2014; 5[1]: 193-200.

Swaminthan S, Wilfred M, Gangadaran P and Ghosh M. Association between lipid profile and macro metals calcium and magnesium. Journal of expermintal sciences 2011; 2[6]: 7-12.

Nasri H and Hamid-Reza Baradaran. Lipids in association with serum magnesium in diabetes mellitus patients. Bratisl Lek Listy 2008; 109[7]: 302-206.

Rashad. J. Belin and Ka He. Magnesium physiology and pathogenic mechanisms that contribute to the development of the metabolic syndrome. Magnesium research 2007; 20[2]: 107-29.

Sakaguchi Y, Shoji T, Hayashi T, Suzuki A, Shimizu M, Mitsumoto K, et al. Hypomagnesemia in type 2 diabetic nephropathy. Diabetes care 2012; 35[7]: 1591-1597.

Ankush RD, Suryakar AN and Ankush NR. Hypomagnesemia in type 2 diabetes mellitus patients: a study on the status of oxidative stress. Indian journal of clinical biochemistry 2009; 24[2]: 184-189.

Supriya, Mohanty S, Murgod R, Kumar Pinnelli VB and Raghavendra SD. Hypomagnesemia, lipid profile and glycosylated haemoglobin in type 2 diabetes mellitus patients. Intl. J. Chem Pharm Res 2012; 1[5]: 116-123.

Dasgupta A, Sarma D and Kaimal Saika U. Hypomagnesemia in type 2 diabetes mellitus. Indian journal of endocrinology and metabolism 2012; 16[6]: 1000-1003.

Lal J, Vasudev K, Kela AK and Jain SK. Effect of oral magnesium supplementation on the lipid profile and blood glucose of patients with type 2 diabetes mellitus. J Ass Physicians India 2003; 51: 37-42.

Rasmussen HS, Aurup P, Goldstein K, Nair MC, Mortensen PB, Larsen. O. G, et al. Influence of magnesium substitution therapy on blood lipid composition in patients with ischemic heart disease. Arch Intern Med 1989; 149[5]: 1050-1053.


  • There are currently no refbacks.